Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 28367 results found since Jan 2013.
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
CONCLUSIONS: Quality measure algorithms should incorporate a risk mortality index related to leukemia vs. other tumors and benign conditions and a risk mortality index related to the treatment status of leukemia (salvage vs. frontline therapy).PMID:37730483 | DOI:10.1016/j.clml.2023.08.016
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Farhad Ravandi Courtney DiNardo Mary Alma Welch Tapan Kadia Hagop Kantarjian Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
CONCLUSIONS: Quality measure algorithms should incorporate a risk mortality index related to leukemia vs. other tumors and benign conditions and a risk mortality index related to the treatment status of leukemia (salvage vs. frontline therapy).PMID:37730483 | DOI:10.1016/j.clml.2023.08.016
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Farhad Ravandi Courtney DiNardo Mary Alma Welch Tapan Kadia Hagop Kantarjian Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
Sci Adv. 2023 Sep 22;9(38):eadg0488. doi: 10.1126/sciadv.adg0488. Epub 2023 Sep 20.ABSTRACTMeasurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we developed a single-cell MRD (scMRD) assay ...
Source: Adv Data - September 20, 2023 Category: Epidemiology Authors: Troy M Robinson Robert L Bowman Sonali Persaud Ying Liu Rosemary Neigenfind Qi Gao Jingping Zhang Xiaotian Sun Linde A Miles Sheng F Cai Adam Sciambi Aaron Llanso Christopher Famulare Aaron Goldberg Ahmet Dogan Mikhail Roshal Ross L Levine Wenbin Xiao Source Type: research
Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax
In this study, prior chemotherapy/allo-SCT and cytogenetic risk were associated with VEN treatment outcomes.PMID:37728705 | DOI:10.1007/s12185-023-03664-1
Source: International Journal of Hematology - September 20, 2023 Category: Hematology Authors: Ryujiro Hara Shinichiro Machida Norisato Hashimoto Daisuke Ogiya Hidetsugu Kawai Shohei Kawakami Sawako Shiraiwa Makoto Onizuka Yoshiaki Ogawa Hiroshi Kawada Kiyoshi Ando Source Type: research
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations
Leuk Res. 2023 Sep 14;134:107388. doi: 10.1016/j.leukres.2023.107388. Online ahead of print.ABSTRACTNumerous recent advances have been made in therapeutic approaches toward acute myeloid leukemia (AML). Since 2017, we have seen eleven novel Food & Drug Administration (FDA)-approved medications for AML, all of which extend beyond the classical cytarabine-based cytostatic chemotherapy. In the recent two decades, the role of immune surveillance in AML has been intensively investigated. The power of one's own innate and adaptive immunity has been harnessed pharmacologically toward the goal of clearance of AML cells. Specif...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Shyam A Patel Elisa Bello Andrew Wilks Jonathan M Gerber Narayanan Sadagopan Jan Cerny Source Type: research
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs
Antimicrob Agents Chemother. 2023 Sep 19:e0048223. doi: 10.1128/aac.00482-23. Online ahead of print.ABSTRACTAntimicrobial resistance has made a sizeable impact on public health and continues to threaten the effectiveness of antibacterial therapies. Novel bacterial topoisomerase inhibitors (NBTIs) are a promising class of antibacterial agents with a unique binding mode and distinct pharmacology that enables them to evade existing resistance mechanisms. The clinical development of NBTIs has been plagued by several issues, including cardiovascular safety. Herein, we report a sub-series of tricyclic NBTIs bearing an amide link...
Source: Antimicrobial Agents and Chemotherapy - September 19, 2023 Category: Microbiology Authors: Chelsea A Mann Jessika J Carvajal Moreno Yanran Lu Sheri Dellos-Nolan Daniel J Wozniak Jack C Yalowich Mark J Mitton-Fry Source Type: research
LC-MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid
Biomed Chromatogr. 2023 Sep 18:e5738. doi: 10.1002/bmc.5738. Online ahead of print.ABSTRACTWe developed and validated sensitive MS/MS methods for the determination of venetoclax, an oral selective B-cell lymphoma-2 inhibitor, in human plasma and cerebrospinal fluid (CSF). Acetonitrile was used as protein precipitant. The mobile phase was 10 mM ammonium formate consisting of 0.1% formic acid and acetonitrile (40:60, v/v). The analytes were separated on an ACQUITY UPLC HSS T3 column (2.1 × 50 mm, 1.8 μm) in 5 min. An API 4000 mass spectrometer was selected to quantify venetoclax and internal standard using m/z 868.3 → 63...
Source: Biomedical Chromatography : BMC - September 19, 2023 Category: Biomedical Science Authors: Yan-Ling Yang Zhou-Yi Qian Yang Zhao Xiang-Long Chen Qiong-Ye Huang Yu-Jiao Guo Lu-Ning Sun Yong-Qing Wang Source Type: research
Lifetime exposure to brominated trihalomethanes in drinking water and swimming pool attendance are associated with chronic lymphocytic leukemia: a Multicase-Control Study in Spain (MCC-Spain)
This study identifies an association of long-term exposure to THMs in drinking water, at concentrations below the regulatory thresholds and WHO guidelines, and swimming pool attendance, with chronic lymphocytic leukemia (CLL). These unprecedented findings are highly relevant since CLL is an incurable cancer with still unknown etiology and because the widespread exposure to chlorination by-products that remain in drinking and recreational water worldwide. Despite the demonstrated carcinogenicity in animals of several chlorination by-products, little is known about their potential risks on human health. This study makes a si...
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Carolina Donat-Vargas Manolis Kogevinas Yolanda Benavente Laura Costas Elias Campo Gemma Casta ño-Vinyals Guillermo Fernandez-Tardon Javier Llorca In és Gómez-Acebo Nuria Aragon és Marina Pollan Delphine Casabonne Cristina M Villanueva Source Type: research
Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia
CONCLUSION: Severe obesity is associated with worse EFS in young adults treated according to the non-HR arms of the NOPHO ALL2008 protocol. Poorer outcome is explained with a higher risk of relapse, possibly due to under treatment, and not caused by excess therapy-related mortality.PMID:37725524 | DOI:10.1080/0284186X.2023.2258450
Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Christina Egnell Helene Hallb öök Mats Heyman Ulla Wartiovaara-Kautto Petter Quist-Paulsen Kjeld Schmiegelow Laimonas Griskevicius Katrin Palk Nina Toft Ulrik Malthe Overgaard Arja Harila Susanna Ranta Source Type: research
Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
CONCLUSIONS: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.PMID:37725576 | DOI:10.1158/1078-0432.CCR-22-2562
Source: Cell Research - September 19, 2023 Category: Cytology Authors: Jonathan Paolino Boris Dimitrov Beth Apsel Winger Angelica Sandoval-Perez Amith Vikram Rangarajan Nicole Ocasio-Martinez Harrison K Tsai Yuting Li Amanda L Robichaud Delan Khalid Charlie Hatton Riaz Gillani Petri Polonen Anthony Dilig Giacomo Gotti Julia Source Type: research
MicroRNA-411-3p motivates methotrexate's cellular uptake and cytotoxicity via targeting Yin-yang 1 in leukemia cells
This study aimed to figure out how microRNA (miR)-411-3p's impacts on methotrexate (MTX)'s cellular uptake and cytotoxicity in acute lymphoblastic leukaemia (ALL) CEM-C1 cells by targeting Yin-yang 1 (YY1). miR-411-3p and YY1 were detected by RT-qPCR or Western blot. Intracellular MTX concentration was measured by enzyme-linked immunosorbent assay. Cell viability and apoptosis were evaluated by CCK-8, clonal formation assay, and flow cytometry. Verification of miR-411-3p and YY1's targeting link was manifested. It came out that miR-411-3p mimic or si-YY1 elevated intracellular MTX, MTX-induced cytotoxicity and apoptosis ra...
Source: Acta Biochim Pol - September 19, 2023 Category: Biochemistry Authors: HuiJing Sun ShuGuang Zhou ZhouSheng Yang MingYu Meng Yan Dai XinYe Li XiaoYu Chen Source Type: research
Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
CONCLUSIONS: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.PMID:37725576 | DOI:10.1158/1078-0432.CCR-22-2562
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Jonathan Paolino Boris Dimitrov Beth Apsel Winger Angelica Sandoval-Perez Amith Vikram Rangarajan Nicole Ocasio-Martinez Harrison K Tsai Yuting Li Amanda L Robichaud Delan Khalid Charlie Hatton Riaz Gillani Petri Polonen Anthony Dilig Giacomo Gotti Julia Source Type: research
LC-MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid
Biomed Chromatogr. 2023 Sep 18:e5738. doi: 10.1002/bmc.5738. Online ahead of print.ABSTRACTWe developed and validated sensitive MS/MS methods for the determination of venetoclax, an oral selective B-cell lymphoma-2 inhibitor, in human plasma and cerebrospinal fluid (CSF). Acetonitrile was used as protein precipitant. The mobile phase was 10 mM ammonium formate consisting of 0.1% formic acid and acetonitrile (40:60, v/v). The analytes were separated on an ACQUITY UPLC HSS T3 column (2.1 × 50 mm, 1.8 μm) in 5 min. An API 4000 mass spectrometer was selected to quantify venetoclax and internal standard using m/z 868.3 → 63...
Source: Biomedical Chromatography : BMC - September 19, 2023 Category: Biomedical Science Authors: Yan-Ling Yang Zhou-Yi Qian Yang Zhao Xiang-Long Chen Qiong-Ye Huang Yu-Jiao Guo Lu-Ning Sun Yong-Qing Wang Source Type: research
